Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. Antibodies
  4. Primary Antibodies
  5. All Primary Antibodies
  6. PIMA541932

Invitrogen™ Mogamulizumab Humanized Recombinant Human Monoclonal Antibody
GREENER_CHOICE

Catalog No. PIMA541932
Change view
Click to view available options
Quantity:
100 μg
Catalog No. Quantity
PIMA541932 100 μg
1 options
This item is not returnable. View return policy

Catalog No. PIMA541932

Supplier: Invitrogen™ MA541932

Only null left
Add to Cart
Add to Cart
This item is not returnable. View return policy

Description

Human Recombinant Monoclonal Antibody

Endotoxin level < 0.01EU/μg by LAL method Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 °C for one week. Store at -20 to -80 °C for twelve months from the date of receipt.

Mogamulizumab is a humanized monoclonal antibody (mAb) directed against CC chemokine receptor 4 (CCR4) for the treatment of Mycosis Fungoides (MF) and Sezary Syndrome (SS), the most common subtypes of cutaneous T-cell lymphoma. Cutaneous T-cell lymphomas occur when certain white blood cells, called T cells, become cancerous; these cancers typically affect the skin, causing various types of skin lesions 8. On August 8 2018, the U. S. Food and pharmaceutical Administration (FDA) approved mogamulizumab injection (also known as Poteligeo) for intravenous use for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sezary syndrome (SS) after at least one prior systemic therapy 7. Mogamulizumab is derived from Kyowa Hakko Kirin's POTELLIGENT (™) technology, which produces antibodies with enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity. Approval in Japan was granted on April 30 2012 by the Japanese Ministry of Health, Labor and Welfare for patients with relapsed or refractory CCR4-positive adult T-cell leukemia-lymphoma 2.
TRUSTED_SUSTAINABILITY

Specifications

Antigen Mogamulizumab Humanized
Applications ELISA, Flow Cytometry
Classification Recombinant Monoclonal
Concentration 2.66 mg/mL
Conjugate Unconjugated
Formulation PBS with no preservative; pH 7.4
Gene Alias AMG-761; KW-0761
Host Species Human
Immunogen Human CCR4/CD194.
Purification Method Protein A
Quantity 100 μg
Regulatory Status RUO
Primary or Secondary Primary
Target Species Human
Content And Storage -20°C, Avoid Freeze/Thaw Cycles
Product Type Antibody
Form Liquid
Isotype IgG1 κ
Target Molecule Chemical
Show More Show Less
Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.